Statera Biopharma Inc

Statera Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. Its proprietary product toll-like receptor (TLR) agonists in the biopharmaceutical industry with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532 have applications in mitigation of radiation injury and neutropenia an anemia. The firm is developing therapies designed to directly elicit within patients a robust and durable response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn’s disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205) in addition to expansion into fibromyalgia and multiple sclerosis. The company was founded by Andrei V. Gudkov and Yakov Kogan on June 5, 2003 and is headquartered in Fort Collins, CO.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FORT COLLINS, Colo., March 15, 2023 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (OTCPK:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, is pleased to announce it has entered into a non-binding letter of intent (the "LOI") with Worksite Labs, Inc. ("WSL"), setting out the initial proposed terms and conditions pursuant to which the Company and Worksite Labs intend to affect a business combination by a merger structure to be determined involving the Company, one or more merger entities of the Company and WSL (the "Proposed Transaction").

Statera Biopharma Signs Letter of Intent for Merger with Worksite Labs

FORT COLLINS, CO / ACCESSWIRE / January 24, 2023 / Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, is pleased to announce it has completed the application process for moving off the OTC Pink Sheets and uplisting to the OTCQB® Venture Marketplace. The application process will not guarantee acceptance of the Company's submission by OTC MARKETS from the PINKS to OTCQB.

Statera Biopharma Announces Completion of Application Process to Uplist to the OTCQB(R) Venture Marketplace

Akebia Therapeutics

The Beachbody Co.

ComSovereign Holding

Faraday Future Intelligent Electric

Nymox Pharmaceutical

Rigel Pharmaceuticals

Sonim Technologies Inc

Tricida Inc

Titan Medical Inc

Penny stocks under $1 to watch this week. The post 10 Top Penny Stocks To Watch Under $1 This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Top Penny Stocks To Watch Under $1 This Week

Penny stocks to buy for under $1 but are they worth the risk? The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 7 Under $1 To Watch Now

FORT COLLINS, CO / ACCESSWIRE / October 27, 2022 / Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that, by decision dated October 26, 2022, a Nasdaq Hearings Panel granted the Company's request for continued listing on The Nasdaq Capital Market ("Nasdaq"), subject to the Company's satisfaction of certain interim milestones and, ultimately, the Company's compliance with all applicable criteria for continued listing on Nasdaq, including the $1.00 bid price and $2.5 million stockholders' equity requirements, by January 31, 2023. About Statera Biopharma Statera Biopharma (formerly Cytocom, Inc.) is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis.

Statera Biopharma Receives Positive Nasdaq Listing Determination

FORT COLLINS, CO / ACCESSWIRE / October 21, 2022 / Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the Company filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 (the "Q1 Form 10-Q") with the Securities and Exchange Commission (the "SEC"). With the Q1 Form 10-Q now on file, the Company is focused on the completion and filing of its Form 10-Q for the quarter ended June 30, 2022.

Statera Biopharma Files Form 10-Q and Reaches Agreement with Silverback Capital and AVOF

FORT COLLINS, CO / ACCESSWIRE / October 17, 2022 / Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced the signing of a binding Memorandum of Understanding ("MOU") with Holobeam Technologies, Inc. ("Holobeam"). Holobeam is the world leader in creating the next generation of holographic medical imaging and therapeutic technologies for the early detection and treatment of cancer and other diseases using their newly patented Holographic Energy Teleportation (HET) technology.

Statera Biopharma Announces Signing of a Binding MOU with Holobeam Technologies to Gain Access to Holobeam's Disruptive Diagnostic Imaging and Therapeutic Technology for Cancer Patients

FORT COLLINS, CO / ACCESSWIRE / October 6, 2022 / Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the audit of the Company's financial statements for fiscal 2021 is complete and that the Company today filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the "Form 10-K") with the Securities and Exchange Commission (the "SEC"). With the Form 10-K now on file, the Company is focused on the completion and filing of the Forms 10-Q for the quarterly periods ended March 31, June 30, and September 30, 2022.

Statera Biopharma Completes Fiscal 2021 Audit; Files Form 10-K

Source: Bukhta Yurii / Shutterstock.com Statera Biopharma (NASDAQ: STAB ) stock is rising higher on Thursday as the company holds a meeting with The Nasdaq Stock Market's Nasdaq Hearings Panel. The meeting with the Nasdaq Hearings Panel has to do with a delisting notice the company received for STAB shares.

What Is Going on With Statera (STAB) Stock Today?

FORT COLLINS, CO / ACCESSWIRE / September 9, 2022 / Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced - as disclosed via the Company's Current Report on Form 8-K as filed with the Securities and Exchange Commission (the "SEC") on Friday, September 9, 2022 - that on September 1, 2022, the Company was notified by the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC that its common stock was subject to delisting unless the Company timely requested a hearing before the Nasdaq Hearings Panel. The Company timely requested a hearing and will request a further stay of any delisting action by Nasdaq pending the hearing, which is scheduled for October 6, 2022, and expiration of any extension that may be granted by the Panel.

Statera Biopharma Receives Nasdaq Listing Determination; Hearing Requested to Address Filing Delinquency

FORT COLLINS, CO / ACCESSWIRE / August 25, 2022 / Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that, as expected, the Company received an additional notice of non-compliance from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") due to the Company's failure to timely file the Form 10-Q for the quarter ended June 30, 2022 with the Securities and Exchange Commission (the "SEC"), as required by Nasdaq Listing Rule 5250(c)(1). As previously disclosed, the Company earlier received notices from Nasdaq regarding its non-compliance with the Rule with respect to the Forms 10-K and 10-Q for the fiscal year ended December 31, 2021 and quarter ended March 31, 2022, respectively.

Statera Biopharma Receives Anticipated Notice of Additional Filing Delinquency from Nasdaq

FORT COLLINS, Colo., June 14, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced the appointment of Certified Public Accountants, BF Borgers CPA PC as the Company's independent accountant to audit the balance sheet of the Company as of December 31, 2021, and the related statements of operations, stockholders' equity and income, and cash flows for the period ended December 31, 2021.

Statera Biopharma Announces BF Borgers CPA PC as Independent Registered Public Accounting Firm

FORT COLLINS, Colo., May 23, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB) (the “Company”), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on May 18, 2022 indicating that, because the Company was delinquent in filing its quarterly report on Form 10-Q on May 15, 2022 for the first quarter ended March 31, 2022, the Company had not complied with Nasdaq Listing Rule 5250(c)(1) for continued listing.

Statera Biopharma Receives Notification Letter from Nasdaq Regarding Form 10-Q Filing

Statera expects to acquire option to license Lay Sciences products for respiratory & gastrointestinal disorders Statera expects to acquire option to license Lay Sciences products for respiratory & gastrointestinal disorders

Statera Biopharma and Lay Sciences Inc. Announce Intent to Enter Strategic Partnership to License the Manufacturing Rights to Certain Lay Sciences IgY Products

Mullen Automotive

Sesen Bio Inc.

Why these three penny stocks shot up during trading on May 5th The post 3 Penny Stocks That Pushed Up During Trading Today  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks That Pushed Up During Trading Today

Clarus Therapeutics Holdings

IT Tech Packaging Inc

Hot penny stocks under $1 to watch this week. The post Hot Penny Stocks To Buy For Under $1 This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks To Buy For Under $1 This Week

Color Star Technology

BitNile Holdings

Are you using these trading strategies when you invest in penny stocks? The post Are These Penny Stocks Trading Strategies on Your List?

Are These Penny Stocks Trading Strategies on Your List?

Today, investors in STAB stock have received a big boost as a a result of a signed commercialization agreement. The post Why Is Statera Biopharma (STAB) Stock Up Today?

Why Is Statera Biopharma (STAB) Stock Up Today?

Exela Technologies

Here's what you need to know about trading penny stocks on April 28th The post Hot Penny Stocks to Buy Today? 3 For Your List  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks to Buy Today? 3 For Your List

Statera Biopharma Inc (NASDAQ: STAB) has entered into a non-binding term sheet with Immune Therapeutics Inc (OTC: IMUN) to sell its naltrexone and met-enkephalin rights. The transaction is contingent upon the negotiation of a definitive agreement and satisfaction of.

Why Are Statera Biopharma Shares Surging Today

FORT COLLINS, Colo., April 27, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB) (the “Company”), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced today that the Company entered into a non-binding term sheet with respect to a strategic agreement with Immune Therapeutics, Inc. (OTC-PINK: IMUN), a drug development and commercialization company, to sell Statera's rights to naltrexone and met-enkephalin. The transaction is contingent upon negotiation of a definitive agreement and satisfaction of a number of closing conditions, including a contingency on Immune Therapeutics financing.

Statera Biopharma and Immune Therapeutics Inc. Announce Strategic Agreement for Rights to Low Dose Naltrexone

FORT COLLINS, Colo., April 22, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB) (the “Company”), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on April 19, 2022 indicating that, because the Company has not yet filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the “Form 10-K”), the Company does not comply with Nasdaq Listing Rule 5250(c)(1) for continued listing.

Statera Biopharma Receives Notification Letter from Nasdaq Regarding Form 10-K Filing

FORT COLLINS, Colo., April 13, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB) (the “Company”), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced today that the Company has agreed to enter into a strategic agreement with Coeptis Therapeutics, Inc. (OTC PINK: COEP), a biopharmaceutical company developing innovative cell therapy platforms for cancer, to sell Statera's rights to Entolimod and other related toll-like receptor 5 (TLR5) agonists. The consummation of the transaction is contingent upon negotiation of a definitive agreement and satisfaction of a number of closing conditions, including a contingency on Coeptis financing.

Statera Biopharma and Coeptis Therapeutics Announce Strategic Agreement for Rights to Entolimod

Artelo Biosciences Inc

Cybin

Meten Holding Group Ltd.

ProQR Therapeutics

Sonnet BioTherapeutics

Penny stocks under $1 to watch right now. The post Best Penny Stocks To Buy Now?

Best Penny Stocks To Buy Now? 7 Stocks Under $1 With Big News Today

Coeptis Therapeutics Holdings, Inc.

Entolimod is currently in clinical development as a potential treatment for acute radiation syndrome with additional preclinical programs advancing in neutropenia and anemia in cancer patients WEXFORD, Pa. , April 13, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. (OTC PINK: COEP), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that the Company has entered into a strategic agreement with Statera Biopharma, Inc. (Nasdaq: STAB) that gives Coeptis the right to acquire Statera's toll-like receptor 5 (TLR5) agonist platform, including entolimod, a clinical-stage product currently being developed as a treatment for acute radiation syndrome.

Coeptis Therapeutics Announces Intent to Acquire TLR5 Agonist Platform, Including Clinical-Stage Asset Entolimod, from Statera Biopharma

News for Statera Biopharma Inc Stock (STAB)